It has come to our notice that certain fraudulent individuals or entities are misusing our Company’s name and TCI’s registered trademarks by promoting and offering regulated and hazardous chemical substances through online platforms like YouTube. We hereby categorically clarify that TCI has no association or connection whatsoever with the products being displayed or sold in the videos. These products have been falsely represented as being associated with TCI, and the unauthorized use of our trademark and brand name is both illegal and misleading. TCI Chemicals markets and sells its products exclusively through its official website and authorized distributors. If you become aware of any such fraudulent activity or require clarification, you may reach out to us at: Sales-IN@TCIchemicals.com. Click Here to View the Caution Notice.
Product Document Searching Made Easy by 2D Code! | [TCIPracticalExample] Goldberg Amination Using...Maximum quantity allowed is 999
Please select the quantity
CAS RN: 2207-75-2 | Product Number: O0164
Potassium Oxonate
×
![]()
×
Purity: >98.0%(T)(HPLC)
Synonyms:
- Allantoxanic Acid Potassium Salt
- Oxonic Acid Potassium Salt
- Potassium Allantoxanate
- Potassium 4,6-Dihydroxy-1,3,5-triazine-2-carboxylate
Product Documents:
| Size | Unit Price | Hyderabad | Japan* | Quantity |
|---|---|---|---|---|
| 5G |
₹2,600.00
|
6 | 2 |
|
| 25G |
₹7,000.00
|
5 | ≥100 |
|
*Upon orders receipt, Hyderabad stocks will be dispatched on the same day.
*Items available in Japan warehouse will be dispatched in 10-12 working days.
*INR price is exclusive of domestic taxes applicable.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
| Product Number | O0164 |
| Purity / Analysis Method | >98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__4H__2KN__3O__4 = 195.18 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
| CAS RN | 2207-75-2 |
| Related CAS RN | 937-13-3 |
| Reaxys Registry Number | 4049961 |
| PubChem Substance ID | 87574167 |
| MDL Number | MFCD00010565 |
Specifications
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
Properties (reference)
| Melting Point | 300 °C |
GHS
Related Laws:
| RTECS# | RR4580000 |
Transport Information:
Application
Potassium Oxonate: An Inhibitor of Orotate Phosphoribosyltransferase (OPRT)
Potassium oxonate is an inhibitor of orotate phosphoribosyltransferase (OPRT) that is an enzyme involved in the biosynthesis of pyrimidine nucleotides and catalyzes the phosphorylation of 5-FU [F0151] to an active metabolite 5-fluorouridine-5'-monophosphate (FUMP). The gastrointestinal toxicity (GIT) of the oral administration of 5-FU is also caused by the phosphorylation by OPRT in the gut wall. Potassium oxonate selectively and competitively inhibits OPRT. As a result, 5-FU associated gastrointestinal toxic effects are reduced. Potassium oxonate is often used as combined agents to enhance the antitumor activity of fluoropyrimidines, such as S-1 (tegafur [F0635] a prodrug of 5-FU, gimeracil [C2243] and potassium oxonate at a molar ratio of 1:0.4:1). (The product is for research purpose only.)
References
- Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators
- Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats
- Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats
- Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats
- Potassium oxonate, an enzyme inhibitor compounded in S-1, reduces the suppression of antitumor immunity induced by 5-fluorouracil
Application
Reagent for hyperuricemia (gout) model
References
- Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents
- Hyperuricemia induced by some antihypertensives and uricosuric drugs in oxonate-treated rats
- Y. Yonetani, M. Ishii, K. Iwaki, Jpn. J. Pharmacol. 1980, 30, 829.
- Use of the uricase-inhibited rat as an animal model in toxicology
- Beneficial effect of rutin on oxonate-induced hyperuricemia and renal dysfunction in mice
PubMed Literature
Documents
Product Articles
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.